PL362375A1 - Zmodyfikowana leptyna o obniżonej immunogeniczności - Google Patents
Zmodyfikowana leptyna o obniżonej immunogenicznościInfo
- Publication number
- PL362375A1 PL362375A1 PL36237502A PL36237502A PL362375A1 PL 362375 A1 PL362375 A1 PL 362375A1 PL 36237502 A PL36237502 A PL 36237502A PL 36237502 A PL36237502 A PL 36237502A PL 362375 A1 PL362375 A1 PL 362375A1
- Authority
- PL
- Poland
- Prior art keywords
- reduced immunogenicity
- modified leptin
- leptin
- modified
- immunogenicity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/20—Protein or domain folding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01102618 | 2001-02-06 | ||
| EP01103954 | 2001-02-19 | ||
| PCT/EP2002/001188 WO2002062833A2 (en) | 2001-02-06 | 2002-02-05 | Modified leptin with reduced immunogenicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL362375A1 true PL362375A1 (pl) | 2004-10-18 |
Family
ID=26076461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL36237502A PL362375A1 (pl) | 2001-02-06 | 2002-02-05 | Zmodyfikowana leptyna o obniżonej immunogeniczności |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040072219A1 (pl) |
| EP (1) | EP1387856A2 (pl) |
| JP (1) | JP2004532618A (pl) |
| KR (1) | KR20030074788A (pl) |
| CN (1) | CN1491232A (pl) |
| BR (1) | BR0207018A (pl) |
| CA (1) | CA2437265A1 (pl) |
| HU (1) | HUP0402071A2 (pl) |
| MX (1) | MXPA03006989A (pl) |
| PL (1) | PL362375A1 (pl) |
| RU (1) | RU2003125638A (pl) |
| WO (1) | WO2002062833A2 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2335107C (en) | 1998-07-28 | 2010-01-19 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Leptin-mediated gene-induction |
| ATE300611T1 (de) | 2000-05-22 | 2005-08-15 | Vlaams Interuniv Inst Biotech | Auf rezeptorgrundlage arbeitende screening- verfahren für protein wechselwirkungen |
| US7235629B2 (en) | 2000-11-14 | 2007-06-26 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Functional fragment of the leptin receptor |
| US7423113B2 (en) | 2004-08-25 | 2008-09-09 | Vib Vzw | Leptin antagonist |
| EP2286837A3 (en) | 2004-11-01 | 2013-09-04 | Amylin Pharmaceuticals, LLC | Treatment of obesity and obesity related diseases |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| US7307142B2 (en) * | 2004-11-26 | 2007-12-11 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Leptin antagonists |
| WO2008157776A2 (en) * | 2007-06-21 | 2008-12-24 | Angelica Therapeutics, Inc. | Modified diphtheria toxins |
| NZ602170A (en) | 2008-02-08 | 2014-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
| WO2009108340A2 (en) * | 2008-02-27 | 2009-09-03 | Temple University - Of The Commonwealth System Of Higher Education | Leptin agonist and methods of use |
| WO2009110944A1 (en) * | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
| WO2011002673A1 (en) * | 2009-07-01 | 2011-01-06 | Temple University - Of The Commonwealth System Of Higher Education | Leptin agonist and methods of use |
| HK1220376A1 (zh) | 2013-03-15 | 2017-05-05 | Angelica Therapeutics, Inc. | 修饰的毒素 |
| CN114634552B (zh) * | 2022-04-14 | 2022-12-13 | 中国农业大学 | 一种抗肥胖十三肽及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| US6225446B1 (en) * | 1995-12-06 | 2001-05-01 | Schering Corporation | Mutational variants of mammalian proteins |
| US6025324A (en) * | 1996-05-15 | 2000-02-15 | Hoffmann-La Roche Inc. | Pegylated obese (ob) protein compositions |
| EP1007648A4 (en) * | 1996-12-20 | 2003-01-15 | Lilly Co Eli | ANTI-OBESITY PROTEINS |
| AU736549B2 (en) * | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| US6835550B1 (en) * | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
| US6838269B1 (en) * | 1998-04-15 | 2005-01-04 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
| JP2002534959A (ja) * | 1998-12-08 | 2002-10-22 | バイオベーション リミテッド | 免疫原性タンパク質の改変方法 |
| BR0207016A (pt) * | 2001-02-06 | 2004-02-03 | Merck Patent Gmbh | Fator neurotrófico derivado de cérebro humano modificado (bdnf) com imunogenicidade reduzida |
-
2002
- 2002-02-05 RU RU2003125638/13A patent/RU2003125638A/ru not_active Application Discontinuation
- 2002-02-05 PL PL36237502A patent/PL362375A1/pl unknown
- 2002-02-05 JP JP2002563185A patent/JP2004532618A/ja not_active Withdrawn
- 2002-02-05 WO PCT/EP2002/001188 patent/WO2002062833A2/en not_active Ceased
- 2002-02-05 HU HU0402071A patent/HUP0402071A2/hu unknown
- 2002-02-05 CN CNA028046110A patent/CN1491232A/zh active Pending
- 2002-02-05 KR KR10-2003-7010323A patent/KR20030074788A/ko not_active Withdrawn
- 2002-02-05 CA CA002437265A patent/CA2437265A1/en not_active Abandoned
- 2002-02-05 MX MXPA03006989A patent/MXPA03006989A/es unknown
- 2002-02-05 BR BR0207018-9A patent/BR0207018A/pt not_active IP Right Cessation
- 2002-02-05 EP EP02719768A patent/EP1387856A2/en not_active Withdrawn
- 2002-02-05 US US10/467,114 patent/US20040072219A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0402071A2 (hu) | 2005-01-28 |
| CN1491232A (zh) | 2004-04-21 |
| KR20030074788A (ko) | 2003-09-19 |
| JP2004532618A (ja) | 2004-10-28 |
| RU2003125638A (ru) | 2005-03-10 |
| MXPA03006989A (es) | 2003-11-18 |
| WO2002062833A2 (en) | 2002-08-15 |
| BR0207018A (pt) | 2004-02-03 |
| WO2002062833A3 (en) | 2003-10-30 |
| EP1387856A2 (en) | 2004-02-11 |
| US20040072219A1 (en) | 2004-04-15 |
| CA2437265A1 (en) | 2002-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL227966A0 (en) | Vaccination kit | |
| GB0103170D0 (en) | Vaccine composition | |
| GB0103171D0 (en) | Vaccine composition | |
| GB0130215D0 (en) | Vaccine | |
| HUP0402259A3 (en) | Vaccines | |
| GB0407935D0 (en) | Vaccine | |
| EP1459776A4 (en) | SYRINGE | |
| HUP0303372A3 (en) | Vaccine | |
| GB0121171D0 (en) | Vaccine | |
| PL362375A1 (pl) | Zmodyfikowana leptyna o obniżonej immunogeniczności | |
| HU0400176V0 (en) | Improved gasketseal | |
| HUP0401121A3 (en) | Modified thrombopoietin with reduced immunogenicity | |
| GB0105238D0 (en) | Vaccines | |
| GB0128651D0 (en) | Syringe | |
| HUP0303523A3 (en) | Modified insulin with reduced immunogenicity | |
| GB0113552D0 (en) | Vaccines | |
| AU2002302785A1 (en) | Vaccines | |
| TW494875U (en) | Sunshade | |
| GB0112989D0 (en) | Sunshade | |
| GB0124137D0 (en) | Vaccine | |
| GB0103867D0 (en) | Vaccine | |
| GB0130823D0 (en) | Vaccine | |
| GB0128312D0 (en) | Vaccine | |
| GB0106589D0 (en) | Vaccine | |
| GB0115496D0 (en) | Vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |